Subject: MJNA is on Fire Up 44% So Far Today

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
We told you about MJNA earlier today and now the stock is up another 27% since then and now up 44% on the day!
Hot Stock to WatchHot Stock to Watch

Company: Medical Marijuana, Inc. (Pink Sheets: MJNA)


Price: 0.0449

Change (%): + 0.0139 (44.84)

Volume: 25,938,497
MJNA Chart

A New Audio Interview With Dr. Stuart Titus, President and Chief Executive Officer of Medical Marijuana, Inc., is Now at

AUSTIN, Texas, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Medical Marijuana, Inc. (OTC Pink:MJNA) and, Inc. (SCV) announced today that a new audio interview with Medical Marijuana, Inc., a leading industrial hemp industry innovator, is now available. The interview can be heard at

Stuart W. Titus, PhD, President and CEO of Medical Marijuana, Inc. called in to to provide the listening audience with his personal insights into the Company's recent news regarding the progress with MJNA's products and portfolio companies such as Real Scientific Hemp Oil(TM), Dixie Botanicals, HempMeds, Kannaway and others. Dr. Titus also gave an update on the international expansion efforts of the portfolio companies as well as some of the recent media and events that have been attended.

"Now that NFL season is in full swing again we are getting more inquiries about the CTE issue that our portfolio company KannaLife is working on addressing. Those inquires relate to the benefits that they have been able to find with the pharmaceutical product that is being developed," states Titus.

In August, KannaLife Sciences, Inc. announced the publication of its global WIPO/PCT Patent WO2015/106108A2 - 'Novel Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Hepatic Encephalopathy.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks